Vitalis Therapeutics Inc. — The charter constituting the independent Data Monitoring Committee for the VitaFlow (VTX-401) pivotal program: composition, blinding, cadence, the four available recommendations, stopping guidance, and the authority boundary against program governance.
1. What a Data Monitoring Committee Is
A Data Monitoring Committee is a small group of independent experts who look at unblinded safety data while a trial is running, and who can tell the sponsor to stop.
Every word of that sentence is doing work.
| Term | Why it matters |
|---|---|
| Independent | No member is employed by Vitalis Therapeutics Inc., holds equity in it, or has any financial interest in the outcome. A committee with a stake in the answer is not oversight. |
| Unblinded | The committee can see which participants received drug and which received placebo. Nobody running the trial can. This is the entire point — safety signals are invisible in blinded data. |
| While it is running | Harm that emerges mid-trial has to be caught mid-trial. A safety review conducted after database lock protects nobody who was enrolled. |
| Can tell the sponsor to stop | The recommendation is binding (C-05). Not advisory, not appealable. |
Somebody has to be able to see. That somebody must not be anyone whose judgment could be affected by what the answer costs. A DMC is the mechanism for holding both of those things at once.
2. Composition
| Member | Discipline | Blinding |
|---|---|---|
| Prof. E. Vartanian | Chair — endocrinology | Independent |
| Dr. L. Okafor | Cardiology | Independent |
| Dr. S. Brennan-Hale | Hepatology | Independent |
| Prof. M. Iwasaki | Independent statistician | Unblinded |
Four members: three clinicians covering the relevant therapeutic areas, and an independent statistician. The disciplines follow the risk profile — endocrinology for the indication, cardiology because of the sub-study under CR-02, and hepatology because gastrointestinal and hepatic signals are the class exposure.
This is not a formality. The independent statistician sits outside the trial's own biostatistics function, prepares the unblinded reports the committee reviews, and is the single point at which treatment assignment becomes visible. Every other person in the program — including the Chief Medical Officer, including the Program Director — remains blinded until database lock.
3. Independence and Conflict of Interest
Independence is the property the whole mechanism rests on, and it is defined by exclusion rather than by declaration.
| Disqualifying interest | Why |
|---|---|
| Employment or consultancy with Vitalis Therapeutics Inc. | The obvious case. Includes recent past employment. |
| Equity, options or any financial stake | A member who benefits from approval is not assessing safety neutrally. |
| Involvement in the trial's design or conduct | A designer assessing their own design is not oversight. |
| Investigator or sub-investigator at a participating site | Would require assessing safety data that includes their own participants. |
| Significant interest in a direct competitor | The mirror-image conflict, and the one most often missed. |
Interests are declared before appointment and re-declared annually. A member who develops a disqualifying interest resigns; recusal from a single meeting is not available, because a DMC member cannot participate in half a safety picture.
3. Cadence & Conduct
The committee meets every 16 weeks, and ad hoc on request of any member.
| Session | Attendance | Content |
|---|---|---|
| Open session | Committee, sponsor representatives, CRO | Enrolment, protocol deviations, data quality, operational matters. Blinded throughout. |
| Closed session | Committee and independent statistician only | Unblinded safety data by treatment arm. No sponsor personnel present, ever. |
| Executive session | Committee members only | Deliberation and formulation of the recommendation. |
Only the recommendation leaves the room. The committee does not share unblinded data, comparative rates, or the reasoning behind a continue recommendation — because any of those would partially unblind the sponsor by inference.
4. Recommendations
Four outcomes are available. Each is communicated in writing to the Chief Medical Officer and copied to the Program Director.
| Recommendation | Effect |
|---|---|
| CONTINUE | The trial proceeds unchanged. No detail given, and none is requested. |
| CONTINUE WITH MODIFICATION | Proceeds with a specified change — a protocol amendment, additional monitoring, an adjusted escalation schedule, or a revised informed consent. |
| PAUSE | Enrolment and/or dosing suspended pending further analysis or a defined follow-up period. Participants already dosed continue to be managed to protocol. |
| STOP | The trial terminates for safety. Binding. Participants transition to protocol-defined follow-up and safety monitoring continues. |
A PAUSE or STOP recommendation is implemented on receipt. It does not go to the Development Committee for a decision, because it is not a decision the Development Committee is permitted to make.
6. Between Meetings, and in Emergencies
A committee that meets every every 16 weeks needs a route for everything that happens in between.
| Situation | Route |
|---|---|
| A single serious unexpected event | Handled through pharmacovigilance and expedited reporting. Does not automatically convene the committee. |
| A case meeting Hy's Law criteria | Ad hoc review within 5 working days, independent of the scheduled cadence. |
| A pattern the sponsor cannot interpret blinded | Sponsor may request an unscheduled review. The committee decides whether to convene. |
| Any member's own concern | Any single member may convene the committee. No quorum of concern is required to raise one. |
| External signal — a class effect reported elsewhere | Reviewed at the next scheduled meeting unless a member escalates sooner. |
Emergency unblinding
Separate from all of the above, and frequently confused with it. An individual participant may be unblinded where knowing the assignment would change their clinical management — a decision made by the treating investigator, not by the sponsor and not by the committee.
Emergency unblinding is clinical, individual, investigator-initiated, and does not involve the DMC at all. Each instance is logged and reported, and a cluster of them is itself a signal.
DMC unblinding is analytical, population-level, and restricted to the independent statistician. A sponsor that responds to a safety concern by proposing to unblind the study has proposed something no one in the program has the authority to do.
5. Stopping Guidance
The committee applies judgment; it does not apply a formula. But three areas carry explicit guidance in this program.
| Area | Guidance |
|---|---|
| Gastrointestinal tolerability | Discontinuation attributable to GI adverse events is the program's differentiation endpoint and its principal clinical risk (R-02). The committee reviews the rate by arm at every meeting. A rate materially above the class benchmark, or a pattern of severe events, warrants CONTINUE WITH MODIFICATION at minimum. |
| Hepatic signals | Any case meeting Hy's Law criteria triggers an ad hoc committee review within 5 working days, independent of the scheduled cadence. |
| Cardiovascular events | Adjudicated MACE in the CR-02 sub-study reviewed at every meeting. The sub-study is powered for non-inferiority, not superiority; the committee's concern is a signal, not the eventual hazard ratio. |
| Deaths | Every death is reviewed individually with narrative and causality assessment, regardless of attributed cause. |
A program that can stop early for good news has an incentive to look for it, and stopping early on a chronic therapy produces a smaller long-term safety database than the label requires. The committee can stop the trial to protect participants. It cannot stop the trial to accelerate the filing, because nobody can.
6. The Authority Boundary
This is the provision that matters most, and the one most often misunderstood by people arriving from industries with a single chain of command.
| Question | Who decides | Can it be appealed? |
|---|---|---|
| Should this program continue to be funded? | Development Committee | To the Board, on ceiling or scope |
| Is it safe to continue dosing? | Data Monitoring Committee | No |
| Should this protocol amendment proceed? | Sponsor, with IRB approval | IRB decision is final at site level |
| Must this adverse event be reported to the agency? | Pharmacovigilance, under regulation | Not a judgment call |
The reason is structural rather than ethical posturing. At the moment a stop recommendation arrives, the sponsor has $125,800,000 committed to Phase 3, a filing date, a launch plan and a commercial forecast. Every incentive points toward finding the recommendation unpersuasive. That is exactly the moment at which the sponsor's judgment is least reliable, and it is why the authority was given away in advance — in writing, before the pressure existed.
Governance systems are built for the day someone very reasonable makes a very reasonable case for continuing.
7. What This Costs the Sponsor
Accepting binding independent oversight is not free, and a program manager should understand the cost rather than treat it as a formality.
- Loss of information. The sponsor cannot see its own safety data by arm until database lock. Planning proceeds on blinded aggregate rates.
- Loss of control over timing. An ad hoc review can be convened by any member, and a pause can arrive at any point in the schedule.
- Irreducible termination risk. No amount of program management reduces the probability of a stop recommendation. It sits outside every mitigation in the RAID Log.
- Cost. Committee fees, the independent statistician, and the unblinded reporting infrastructure, carried within the Phase 3 pool.
8. Interface With Program Governance
Two committees, adjacent, with a clean seam.
| Development Committee | Data Monitoring Committee | |
|---|---|---|
| Constituted by | Board of Vitalis Therapeutics Inc. | The sponsor, but independent of it |
| Membership | Sponsor executives | External experts, no sponsor personnel |
| Sees unblinded data | Never | Yes, via the independent statistician |
| Decides | Funding, scope, gate outcomes | Participant safety |
| Cadence | At gates, plus monthly checkpoints | Every 16 weeks, and ad hoc on request of any member |
| Can overrule the other | No | Effectively yes — a stop ends the program |
In practice the interface is narrow and one-directional. The Development Committee is notified of DMC recommendations and their consequences; it does not review them, question them, or vote on them. Where a recommendation has funding consequences — a pause extends the schedule, a modification adds cost — those are Development Committee matters, taken as given from the recommendation rather than as an opportunity to revisit it.
If a stop recommendation had arrived
Dosing would have ceased on receipt. The Chair would have convened an extraordinary gate within five working days. The available outcomes under the Development Committee Charter would have been HOLD pending analysis or KILL; GO would not have been available, because the criterion that makes it available is no longer satisfiable. Participants already dosed would have transitioned to protocol-defined follow-up, funded separately from the program's commercial termination — a program may be stopped commercially while its clinical obligations continue.
10. Records and Terminology
The committee keeps two sets of minutes.
| Record | Contents | Access |
|---|---|---|
| Open session minutes | Attendance, operational discussion, the recommendation | Sponsor, CRO, regulators on request |
| Closed session minutes | Unblinded data reviewed, deliberation, reasoning | Committee and independent statistician only, until database lock |
Closed minutes are released to the sponsor after lock and form part of the NDA submission. They are what allows a reviewer to see that safety oversight actually occurred rather than merely existed on paper.
On the name
DMC, IDMC (Independent Data Monitoring Committee) and DSMB (Data Safety Monitoring Board) refer to the same body. Usage differs by region, sponsor and era — DSMB is more common in academic and NIH-funded work, DMC and IDMC in industry. Nothing turns on the choice, but a charter should use one term consistently, and this one uses DMC throughout.